Comparison · NCT00374322-44054de8
Lapatinib 1500 mg vs Placebo: Number of Participants With CNS Recurrence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lapatinib 1500 mg vs Placebo: Number of Participants With CNS Recurrence. Trial comparisons, record NCT00374322-44054de8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00374322-44054de8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00955 | 0.00579 | 0.0157 | wilson | |
| Risk in group 2 | 0.0133 | 0.00873 | 0.0203 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00378 | -0.0117 | 0.0039 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.717 | 0.371 | 1.38 | log | |
| Odds ratio, group 1 over group 2 | 0.714 | 0.367 | 1.39 | log | |
| Number needed to treat, for one fewer participant with the outcome on Lapatinib 1500 mg than on Placebo | 265 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lapatinib 1500 mg | Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal. | 15 | 1,571 | OG000 |
| Group 2 | Placebo | Participants received matching placebo orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal. | 21 | 1,576 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With CNS Recurrence
- Description
- The number of participants experiencing a CNS recurrence was summarized.
- Time frame
From the date of randomization until the date of the first occurrence of a CNS recurrence (assessed up to 6 years [1 year of treatment and 5 years of follow-up; median of 5.3 years for final analysis])
- Population
- ITT Population. Data for the end-of-study analysis (conducted in 2013) are reported.
Source ClinicalTrials.gov
Trial
- Title
- Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
- NCT number
- NCT00374322
- Phases
- PHASE3
- Conditions
- Neoplasms, Breast
- Interventions
- lapatinib, placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2014-08-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00374322?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00374322-44054de8